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Systemic lupus erythematosus is a prototypic 
autoimmune disease with complex and unclear 
etiology (Rahman and Isenberg, 2008). Most 
studies of this disease have focused on the defects 
of B and T cell tolerance as an underlying cause 
of the disorder. Recently, however, greater   
attention has been given to the pathological 
roles of myeloid cells in autoimmunity (Cohen 
et al., 2002; Hanada et al., 2003; Zhu et al., 
2005; Stranges et al., 2007).
Mice  lacking  Lyn,  an  Src  family  kinase 
mainly expressed in B and myeloid cells, are 
a well-established model of lupus-like autoim-
munity (Xu et al., 2005). lyn/ mice develop 
progressive autoimmunity characterized by auto-
antibody  production,  lymphocyte  activation, 
immune complex deposition, and nephritis 
(Hibbs  et  al.,  1995;  Nishizumi  et  al.,  1995; 
Chan et al., 1997; Yu et al., 2001). The devel-
opment of autoimmunity in lyn/ mice has 
been mainly attributed to alterations in B cell 
signaling thresholds, leading to abnormal B cell 
selection and/or tolerance resulting in produc-
tion of self-reactive antibodies (Chan et al., 
1998; Xu et al., 2005). The Lyn mutation directly 
affects B cell development, as lyn/ mice have 
an 30–50% reduction in mature B cell num-
bers because of the reduction of specific B cell 
subtypes such as marginal zone and follicular 
B cells (Xu et al., 2005; Gross et al., 2009).
Lyn is also expressed in innate immune 
cells, where it regulates cell signaling thresholds 
to several CSFs, such as G-CSF, GM-CSF, and 
M-CSF (Harder et al., 2001, 2004; Scapini et al., 
2009). lyn/ myeloid cells are hyperresponsive 
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Autoimmunity is traditionally attributed to altered lymphoid cell selection and/or  
tolerance, whereas the contribution of innate immune cells is less well understood.  
Autoimmunity is also associated with increased levels of B cell–activating factor of the 
TNF family (BAFF; also known as B lymphocyte stimulator), a cytokine that promotes 
survival of self-reactive B cell clones. We describe an important role for myeloid cells  
in autoimmune disease progression. Using Lyn-deficient mice, we show that overproduc-
tion of BAFF by hyperactive myeloid cells contributes to inflammation and autoimmunity 
in part by acting directly on T cells to induce the release of IFN-. Genetic deletion of  
IFN- or reduction of BAFF activity, achieved by either reducing myeloid cell hyperproduction 
or by treating with an anti-BAFF monoclonal antibody, reduced disease development  
in lyn/ mice. The increased production of IFN- in lyn/ mice feeds back on the myeloid 
cells to further stimulate BAFF release. Expression of BAFF receptor on T cells was  
required for their full activation and IFN- release. Overall, our data suggest that the 
reciprocal production of BAFF and IFN- establishes an inflammatory loop between 
myeloid cells and T cells that exacerbates autoimmunity in this model. Our findings  
uncover an important pathological role of BAFF in autoimmune disorders.
© 2010 Scapini et al.  This article is distributed under the terms of an Attribution–
Noncommercial–Share Alike–No Mirror Sites license for the first six months after 
the publication date (see http://www.rupress.org/terms). After six months it is 
available under a Creative Commons License (Attribution–Noncommercial–Share 
Alike 3.0 Unported license, as described at http://creativecommons.org/licenses/
by-nc-sa/3.0/).
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RESULTS
Lyn-deficient myeloid cells overproduce BAFF
As seen in other autoimmune-prone mice, the serum levels of 
BAFF were significantly elevated in lyn/ mice at 2 mo of age 
and progressively increased over time, reaching 3.1–4.8 times 
the WT levels (Fig. 1 A). The increased BAFF serum levels in 
young lyn/ mice could be a consequence of the 30–50% 
reduction in mature B cell numbers caused by Lyn deficiency 
(Xu et al., 2005); however, this did not explain the progressive 
rise in BAFF with age, which is likely caused by overproduc-
tion of the cytokine by lyn/ myeloid cells. Indeed, starting 
between 3–4 mo of age lyn/ mice manifested progressive 
myeloproliferation (Fig. 1 B), culminating at 10 mo of age in 
a dramatic expansion of granulocyte (Mac-1high7/4intGR-1high), 
monocyte  (Mac-1high7/4highGR-1low),  macrophage  (F4/80+), 
and DCs (CD11c+) compartments (Fig. S1 A). Correlated with 
the myeloid expansion, the levels of BAFF mRNA expression 
in total spleen or sorted splenic macrophages/DCs from lyn/ 
mice (age 6–8 mo) were elevated (Fig. 1 C). Notably, there 
was no significant increase of BAFF mRNA expression in the 
spleens of young lyn/ mice before the onset of myelopro-
liferation (unpublished data), indicating that expansion/activa-
tion of myeloid cells and not stromal cells (Lesley et al., 2004) 
is likely responsible for the increased splenic BAFF mRNA ex-
pression observed in old lyn/ mice. In line with these find-
ings, we observed that cultured bone marrow–derived (BMD) 
macrophages and DCs from lyn/ mice overproduced BAFF, 
as assessed at both the mRNA and protein level, primarily in 
response to IFN- stimulation (Fig. 1, D and E). In combination 
with M-CSF and GM-CSF, IFN- induced even higher re-
lease of BAFF without altering mRNA levels (Fig. 1, D and E) 
because of the proliferative effects of these CSFs (as confirmed 
by proliferation assays run in parallel; not depicted). These 
data suggest that the overproduction of BAFF by lyn/ mac-
rophages and DCs in vivo is likely caused by both increased   
proliferation and exaggerated responses to IFN-. Indeed,   
in vitro, lyn/ macrophages and DCs demonstrated increased 
STAT-1  phosphorylation  and  IP-10/CXCL10  production   
after IFN- stimulation (Fig. S1, B and C). Neutrophils are 
also a known source of BAFF (Scapini et al., 2008); indeed, 
Lyn-deficient BMD neutrophils released higher levels of 
BAFF than WT neutrophils in response to proinflammatory 
mediators such as fMLP, TNF, and IFN- but not to PMA, 
which activates neutrophils independently of Src family kinases   
(Fig. S1 D). These data suggest that besides splenic macrophages 
and DCs, other myeloid cell types (granulocytes and mono-
cytes) present in the spleens of old lyn/ mice might contrib-
ute to the observed increased BAFF mRNA expression in the 
total spleen. In contrast, there was no difference in the low 
levels of BAFF mRNA present in T cells from WT versus 
lyn/ mice (unpublished data). The BAFF protein released 
by lyn/ myeloid cells was biologically active because it sup-
ported B cell survival in vitro (Fig. S2). These data demonstrate 
that overproduction of BAFF by hyperactive lyn/ myeloid 
cells may be responsible for the progressive increase in serum 
BAFF observed over time in lyn/ mice.
to engagement of surface integrins, leading to hyperadhesion, 
enhanced respiratory burst, and increased secondary granule re-
lease (Pereira and Lowell, 2003). Despite this experimental evi-
dence in vitro, the contribution of myeloid cells to the development 
of autoimmunity in lyn/ mice has not been investigated.
Autoimmunity is often associated, both in mice and humans, 
with excess production of B cell–activating factor of the TNF 
family (BAFF), a member of the TNF superfamily of cyto-
kines also known as B lymphocyte stimulator (Mackay et al., 
2007; Stadanlick and Cancro, 2008; Mackay and Schneider, 
2009). Both autoimmune-prone mice (such as MRLlpr/lpr and 
NZB×W F1) and human patients suffering from autoimmune 
disorders such as systemic lupus erythematosus or rheumatoid 
arthritis have elevated serum levels of BAFF (Kalled, 2005; 
Mackay and Schneider, 2009). This cytokine is thought to 
exert its pathogenic role, under conditions of excess production, 
through its ability to support survival and proliferation of   
autoreactive B cells, which have a higher BAFF dependence 
(Lesley et al., 2004). However, in addition to its effect on   
B cells, recent work has suggested that BAFF can also pro-
mote T cell activation (Ye et al., 2004; Sutherland et al., 
2005; Mackay and Leung, 2006; Lai Kwan Lam et al., 2008). 
Despite this evidence, it remains unclear if BAFF exerts a di-
rect pathogenic role on T cells in vivo during autoimmunity. 
Furthermore, the mechanisms responsible for deregulated 
BAFF production in autoimmune diseases have been poorly 
investigated. Studies in mice have shown that there are two 
distinct pools of BAFF: a constitutive pool produced by stro-
mal cells, which is thought to regulate the size and matura-
tion stage of the peripheral B cell compartment, and an accessory 
pool, produced mainly by myeloid cells during inflammatory 
or immune responses (Schneider, 2005). Which of these two 
pools contributes to autoimmune pathologies is unknown. 
Different attempts to neutralize BAFF activity in autoimmune 
disorders have been performed in both mice and humans, but 
despite a general agreement on the efficacy of the treatments, 
the mechanisms of this protection are still not fully understood 
(Ding, 2008; Ramanujam and Davidson, 2008; Moisini and 
Davidson, 2009).
Another important cytokine that has been shown to be 
involved in lupus pathogenesis is IFN-. Several studies in 
MRLlpr/lpr and NZB×W F1 autoimmune-prone mice ob-
served  significant  reduction  of  histological  and  serological 
disease characteristics, and extended survival in these strains 
after IFN- genetic deletion or after anti–IFN- mAb treat-
ment (Theofilopoulos et al., 2001).
We  found  that  the  levels  of  BAFF  were  dramatically 
higher in the sera of lyn/ mice compared with WT animals, 
and that the deregulated production of BAFF by lyn/ myeloid 
cells can contribute to autoimmunity in these animals by af-
fecting not only B cell activation but, more interestingly, by 
directly promoting T cell activation and IFN- production 
by the latter cells. These findings shed new insight on the 
pathological  mechanisms  of  interplay  between  innate  and 
adaptive immunity, as well as the consequences of BAFF and 
IFN- overproduction, in autoimmune disorders.JEM VOL. 207, August 2, 2010 
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compared with WT animals (Fig. 2 B). Coinci-
dent with the rise in these cytokines, the numbers 
of  activated  (CD69+)  and  effector  (CD44high 
CD62L) T cells (of both the CD4 and CD8 
subtypes) in the spleens of lyn/ animals also 
progressively  increased  (Fig.  2  C,  left;  and 
Fig. 2 D, top and middle). Most importantly, a 
large number of the activated T cells (of both the 
CD4 and CD8 subtypes) were producing IFN- 
(Fig. 2 C, right; and Fig. 2 D, bottom). Because 
Lyn kinase is not expressed in the T cell lineage, 
the development of progressive T cell activation 
and IFN- production in lyn/ mice must be 
caused by some non–T cell factor that is acting 
on these cells. Collectively, these initial find-
ings suggested that there was a strong kinetic 
correlation between a progressive increase in 
myeloproliferation, T cell activation, BAFF, and 
IFN- overproduction in lyn/ mice. Interest-
ingly, the lymph nodes of the lyn/ mice did not display ev-
idence of myeloid cell accumulation and had lower numbers 
of activated T cells compared with the spleen.
Block in myeloid cell activation/proliferation  
by the deficiency of Hck and Fgr reduces BAFF  
production and T cell activation in lyn/ mice
To understand the contribution of myeloid cell hyperactiva-
tion/proliferation to the elevated serum BAFF and IFN- as 
Increased IFN- production by activated T cells  
in lyn/ mice
Given that IFN- proved to be the major inducer of BAFF 
production by lyn/ macrophages and DCs in vitro, we ex-
amined the levels of this cytokine in vivo. lyn/ mice mani-
fested a progressive increase in serum levels of IFN-, which 
began to rise between 3 and 4 mo of age coincident with   
rising BAFF levels (Fig. 2 A). By 6–8 mo of age, lyn/ 
mice displayed dramatically elevated splenic IFN- mRNA   
Figure 1.  Increased BAFF production by lyn/  
myeloid cells in vivo and in vitro. (A) ELISA of BAFF serum 
levels in WT and lyn/ mice. Statistical differences in 
BAFF serum levels between WT and lyn/ mice are indi-
cated at each time point. Statistical differences in serum 
BAFF between 2- and 10-mo-old lyn/ mice are also 
reported. Each symbol represents the BAFF serum level of 
an individual mouse. Horizontal bars represent means. 
Data are representative of two independent kinetic ex-
periments. (B) Single-cell suspensions of spleens from 
WT or lyn/ mice at different ages were prepared, 
counted, and stained for FACS analysis. The total number 
of Mac-1+ myeloid cells is reported. Data are expressed 
as means ± SEM (n = 6–10 mice per time point). Data are 
pooled from two separate kinetic experiments. (C) BAFF 
mRNA expression in total spleen or sorted splenic macro-
phages and DCs (F4/80+CD11c+) from 6–8-mo-old WT or 
lyn/ mice. Horizontal bars represent means. Data are 
representative of one end-point experiment (n = 4–6).  
(D and E) BAFF mRNA expression and protein release in vitro 
by BMD macrophages or BMD DCs, prepared as described 
in Materials and methods from 2–3-mo-old WT or lyn/ 
mice, were determined by quantitative RT-PCR and ELISA, 
respectively. BAFF mRNA expression (24 h; left) and pro-
tein release (48 h; right) by BMD macrophages (D) or 
BMD DCs (E) in response to the indicated stimuli. Means ± 
SEM of data from four to six independent experiments 
are reported. *, P < 0.05; **, P < 0.01; ***, P < 0.001.1760 BAFF, IFN-, and myeloid cells in autoimmunity | Scapini et al.
levels in splenic macrophages and DCs (or total spleen cells) 
was dramatically lower in the HFL/ mice compared with 
the lyn/ animals (Fig. 3 D, left). The HFL/ mice also had 
significantly lower numbers of activated T cells, lower numbers 
of IFN-–producing T cells, and lower amounts of splenic 
IFN- mRNA (Fig. 3, B and D, right), despite the fact that 
none of these kinases are present in T cells. On the other 
hand, the activated B cell phenotype (including the enhanced 
expression of co-stimulatory molecules) was largely unchanged 
in HFL/ compared with lyn/ mice, in line with the fact 
that Hck and Fgr are not expressed in most B cell types   
(Fig. 3 B, right; and Fig. S3 B). Furthermore, the hyperactive 
B cells in the HFL/ animals produced levels of total Ig and 
autoreactive anti-dsDNA and anti-RNA antibodies at levels 
just below the single mutant lyn/ mice (Fig. S3 C and not 
depicted). A more detailed characterization of the autoanti-
bodies present in the sera of HFL/ mice revealed that, similar 
to lyn/ mice, IgG2a/c was the main pathogenic isotype for 
both anti-dsDNA and anti-RNA antibodies (Fig. S3 C and 
not depicted). Furthermore, the serum of both HFL/ and 
lyn/ mice contained high levels of antinuclear autoanti-
bodies (ANAs), which displayed strong nuclear homoge-
neous and nuclear speckled staining patterns, indicative of 
both anti-DNA and anti-RNA antibodies (Fig. S3 D). The 
reduction in myeloproliferation and T cell activation correlated 
well as to the autoimmunity in lyn/ mice, we investigated 
how reduction in myeloid cell expansion/activation would 
affect these phenomena. For this purpose, we analyzed the 
phenotype of Hck/Fgr/Lyn triple-deficient (HFL/) mice. 
These three kinases make up the primary Src family members 
expressed in myeloid leukocytes; however, they play differ-
ent roles, with Lyn being predominantly a negative regulator 
of myeloid cell reactivity, whereas Hck and Fgr contribute to 
positive signaling (Lowell, 2004; Berton et al., 2005; Scapini 
et al., 2009). Myeloid cells lacking all three of these kinases 
show a hypoproliferative phenotype in response to cytokine 
stimulation in vitro because of impaired STAT phosphoryla-
tion (unpublished data; Rane and Reddy, 2002). As a result, 
the HFL/ mice themselves lack the severe splenomegaly 
and myeloproliferation (in particular of macrophages and 
DCs) seen in the lyn/ animals (Fig. 3, A and B, left; and 
Fig. S3 A), whereas the total number of B and T cells was 
similar (Fig. 3 B, left). These mice therefore served as an im-
portant  model  to  test  if  reduction  in  myeloproliferation 
would affect BAFF, IFN-, and autoimmune progression. 
The HFL/ mice showed elevated BAFF levels early in life, 
similar to the lyn/ animals and consistent with the B cell 
lymphopenia in both strains; however, the HFL/ strain 
failed to manifest the progressive rise in serum BAFF seen in 
the single mutant lyn/ animals (Fig. 3 C). BAFF mRNA 
Figure 2.  Progressive increase in T cell activation and IFN- production in aging lyn/ mice. (A) IFN- serum levels in WT and lyn/ mice 
were assessed by ELISA. Each symbol represents the IFN- serum level of an individual mouse. Horizontal bars represent means. Data are pooled from 
three independent kinetic experiments (n = 6–10). (B) IFN- mRNA expression in total spleens from of 6–8-mo-old WT or lyn/ mice. Horizontal bars 
represent means. Data are representative of one end-point experiment (n = 3–4). (C and D) Single-cell suspensions of spleens from WT or lyn/ mice 
at different ages were prepared, counted, and stained for FACS analysis. (C) Total number of TCR+CD44highCD62L (effector cells; left) and TCR+IFN-+ 
(IFN-–producing cells; right) are reported as evidence of T cell activation. The number and percentage of IFN-–producing T cells were evaluated by 
intracellular staining after ex vivo stimulation of splenocytes with PMA plus ionomycin for 4 h. Data are expressed as means ± SEM (n = 6–10 mice per 
time point). Data are pooled from two independent kinetic experiments. *, P < 0.05; **, P < 0.01. (D) Representative FACS plots demonstrating T cell 
activation in 10-mo-old lyn/ mice by analysis of the expression of CD69, CD44, CD62L, and IFN- are reported. Data are representative of >40 mice 
for each genotype analyzed at end-point experiments.JEM VOL. 207, August 2, 2010 
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strongly reduced in the kidneys of HFL/ mice as compared 
with lyn/ mice (Fig. 3 F). These data demonstrate that a 
reduction  of  myeloid  cell  hyperreactivity  in  lyn/  mice, 
achieved by removal of additional Src family kinases, leads to 
reduction in serum BAFF, T cell activation, IFN- produc-
tion, and nephritis.
Myeloid-specific Lyn deficiency is sufficient to induce BAFF 
overproduction and autoimmunity
To further explore the interrelationship between myelopro-
liferation, BAFF, IFN-, and autoimmune nephritis, we gener-
ated chimeric mice lacking Lyn kinase specifically in myeloid 
with a dramatic reduction in nephritis (interstitial nephritis 
more than reduced glomerulonephritis) in HFL/ mice 
(Fig. S3 E). Compared with lyn/ mice, HFL/ animals 
showed reduced numbers of Mac-1+ myeloid cells (mainly 
macrophages and DCs) and activated T cells infiltrating the 
kidneys (Fig. 3 E and Table I), despite the fact that glomeru-
lar IgG immune complex and complement factor 3 (C3)   
deposits were still evident, albeit at reduced levels (Fig. S3 F 
and Table I). The latter were probably responsible for a 
smaller reduction in glomerulonephritis than in interstitial 
nephritis in HFL/ mice as compared with lyn/ mice. 
The renal expression of BAFF and IFN- mRNAs was also 
Figure 3.  Hck and Fgr deficiency  
reduces BAFF serum levels, blocks  
splenomegaly, and improves nephritis in 
lyn/ mice. (A) Each symbol represents the 
weight of an individual spleen from 8–10- 
mo-old WT, lyn/, or HFL/ animals. Horizontal 
bars represent means. Data are pooled from 
two independent end-point experiments  
(n = 6–8). (B) Single-cell suspensions of 
spleens from 8–10-mo-old WT, lyn/, or 
HFL/ mice were counted and stained for 
FACS analysis. (left) The absolute number of 
total, myeloid plus DC (Mac1+CD11c+),  
B (CD19+), and T (TCR+) cells. (right) The 
absolute number of activated lymphocytes, 
CD19+CD69+ and CD19/B220int/nullCD138+, are 
reported as evidence of B cell activation, 
whereas TCR+CD69+, TCR+CD44highCD62L 
(effector cells), and TCR+IFN-+ (IFN-–
producing cells, evaluated as described in  
Fig. 2) cells are reported as evidence of T cell 
activation. Data are expressed as means ± 
SEM (n = 8 mice per group). Statistical  
differences of HFL/ versus lyn/ mice or 
HFL/ versus WT mice are reported. Data are 
pooled from two independent end-point 
experiments. (C) BAFF serum levels in WT, 
lyn/, or HFL/ mice assessed by ELISA. 
Horizontal bars represent means. Data are 
pooled from two independent kinetic experi-
ments (n = 5–8). (D) BAFF (left) and IFN- 
(right) mRNA expression in sorted splenic 
macrophages and DCs (F4/80+CD11c+) or 
total spleens from 6–8-mo-old WT, lyn/, or 
HFL/ mice. Horizontal bars represent means. 
Data are representative of one end-point 
experiment (n = 4–6). (E, left) Representative 
H&E staining of kidney sections from 8–10-
mo-old WT, lyn/, or HFL/ mice. Bars,  
100 µm. (middle and right) Representative 
FACS plot analysis of CD45+ myeloid cells 
(Mac-1+; middle) and activated/effector T cells 
(CD44highCD62L) infiltrating the kidneys of 
8–10-mo-old WT, lyn/, or HFL/ mice are 
reported (right). Data are representative of 
10–12 mice for each genotype analyzed at end-point experiments. (F) BAFF (top) and IFN- (bottom) mRNA expression in total kidneys from 8–10-
mo-old WT, lyn/, or HFL/ mice. Data are representative of one independent end-point experiment (n = 3–4). *, P < 0.05; **, P < 0.01; ***, P < 0.001.1762 BAFF, IFN-, and myeloid cells in autoimmunity | Scapini et al.
chimeras also became activated with a significant expansion 
of CD69+, effector, or IFN-–secreting cells, reaching levels 
similar to unmanipulated lyn/ mice (Fig. 4 C, right). Aged 
lyn/rag/ chimeras also developed obvious evidence of 
kidney inflammation with increased interstitial nephritis and 
cellular infiltration mainly by Mac-1+ myeloid cells and acti-
vated T cells (Fig. 4 E, Fig. S4 E, and Table I). Consistent 
with the serological data, immunofluorescent staining revealed 
increased IgM deposits in the glomeruli of lyn/rag/-WT 
chimeras (Fig. S4 F and Table I). Interestingly, probably because 
of a lack of glomerular IgG and C3 deposits, lyn/rag/-
WT chimeras manifested a lower level of glomerulonephritis 
compared with unmanipulated lyn/ mice. These data dem-
onstrate that myeloid-restricted deletion of Lyn is sufficient 
to induce elevated serum levels of BAFF, myeloproliferation, 
B cell activation, T cell activation with increased IFN-  
production, and autoimmune nephritis.
IFN- deficiency reduces BAFF serum levels and ameliorates 
autoimmunity in lyn/ mice
The described observations suggest a pathological interrela-
tionship between BAFF release by myeloid cells and IFN- 
production by T cells that may contribute to the develop-
ment of nephritis in lyn/ mice. To further explore this, we 
generated animals deficient for both Lyn and IFN- (lyn/ 
IFN/). We found that many of the Lyn deficiency– 
induced phenotypes were attenuated in lyn/IFN/ mice. 
Serum BAFF levels were strongly reduced in aged lyn/ 
IFN/ mice, as was BAFF mRNA expression in splenic 
myeloid cells (or total spleen cells) compared with single mu-
tant lyn/ mice (Fig. 5, A and B, left). Importantly, IFN- 
cells. To achieve this, we crossed lyn/ mice to rag/ animals 
and used bone marrow from the CD45.2+ lyn/rag/ mice 
or rag/ mice (as controls), mixed with CD45.1+ WT bone 
marrow (in a ratio of 75:25%) to reconstitute the hematopoi-
etic system of lethally irradiated CD45.1+ WT animals. WT 
control chimeras were generated by reconstituting lethally ir-
radiated  CD45.2+  WT  animals  with  CD45.1+  WT  bone 
marrow (Fig. S4 A). The lyn/rag/ and rag/ mixed bone 
marrow chimeras (referred to as lyn/rag/-WT and rag/-
WT chimeras) both had modestly elevated serum BAFF lev-
els at 2 mo after reconstitution because of mild lymphopenia 
caused by the 75% rag/ bone marrow cells; however, only 
the lyn/rag/-WT chimeras showed a progressive increase 
in BAFF with age (Fig. 4 A). Similarly, starting between 3 and 
4 mo of age, lyn/rag/-WT chimeras progressively devel-
oped splenomegaly and myeloproliferation (Fig. 4, B and C, 
left; and Fig. S4 B) that, by 10 mo of age, were indistinguish-
able from unmanipulated lyn/ mice. The WT B cells present 
in the lyn/rag/-WT chimeras developed a hyperactivated 
phenotype with increased numbers of CD69+ B cells and 
plasma cells (Fig. 4 C, right) that produced high levels of   
autoreactive IgM antibodies (Fig. 4 D). Both lyn/rag/-
WT and rag/-WT chimeras developed increased anti- 
dsDNA (and anti-RNA; not depicted) IgM autoantibodies 
and total IgM compared with control WT chimeras, with 
lyn/rag/-WT chimeras being more severe (Fig. S4 C). 
Furthermore,  50–60%  of  lyn/rag/-WT  chimeras  (but 
none of the rag/-WT or WT chimeras) had serum ANA 
autoantibodies that showed a mild speckled staining pattern 
indicative of the presence of low levels of anti-RNA IgG anti-
bodies (Fig. S4 D). The WT T cells in the lyn/rag/-WT 
Table I.  Increased infiltration of leukocytes into the kidneys of lyn/ mice and lyn/rag/ chimeras
Regular mice Bone marrow chimeras
Genotype WT lyn/ HFL/ lyn/ IFN/ WT rag/ lyn/rag/
CD45+ (×105) 7.5 ± 1.5 22 ± 3 9.5 ± 1*** 10.7 ± 1*** 8.2 ± 1.7 9.7 ± 1 15.5 ± 1**
CD45+CD19+ (×105) 2 ± 0.4 0.9 ± 0.4 1.5 ± 0.5 1 ± 0.3 1.9 ± 0.2 1.2 ± 0.1 1 ± 0.1
CD45+Mac-1+ (×105) 3 ± 0.6 15 ± 2 4 ± 1*** 5.6 ± 1*** 3. ± 0.3 4 ± 0.3 9.2 ± 1**
CD45+TCR+ (×105) 2.5 ± 0.5 6 ± 1 3.5 ± 0.6* 4 ± 0.6* 3.2 ± 0.6 4.2 ± 0.6 5.1 ± 0.7
CD45+TCR+CD44highCD62L (%) 35 ± 4 80 ± 5 45 ± 5*** 50 ± 3*** 42 ± 3 51 ± 6 75 ± 5**
Histological score
Glomerulonephritis 0 2.8 ± 0.1 1.7 ± 0.1** 1.1 ± 0.2*** 0 0.6 ± 0.1 1.6 ± 0.12*
Interstitial nephritis 0 2.5 ± 0.2 1.1 ± 0.1*** 0.5 ± 0.1*** 0 0.2 ± 0.04 2.3 ± 0.2**
Immunofluorescence  
staining intensity
IgM deposit score +/ +++ +++ +++ +/ ++ +++
IgG deposit score  ++ + +/ - - 
C3 deposit score  +++ + +/ - - 
Kidneys were isolated from 8–12-mo-old mice (either regular animals or bone marrow chimeras) of the indicated genotypes, processed, and analyzed for infiltration of 
leukocytes by flow cytometry, as described in Materials and methods. The absolute number of total leukocytes (CD45+), B cells (CD19+), myeloid cells (Mac-1+), and T cells 
(TCR+), and the percentage of activated effector T cells (TCR+CD44highCD62L) are reported as means ± SEM (n = 8–12). Statistical differences between HFL/ or lyn/ 
IFN/ versus lyn/ mice are reported. Similarly, statistical differences between rag/-WT versus lyn/rag/-WT chimeras are reported. *, P < 0.05; **, P < 0.01;  
***, P < 0.001. Histological analysis of renal disease as well as of Ig immune complex and C3 deposit immunofluorescent staining intensity was performed as described in 
Materials and methods. Data are representative of 10–20 mice for each genotype analyzed at end-point experiments.JEM VOL. 207, August 2, 2010 
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mouse models of lupus-like disease (Balomenos et al., 1998; 
Theofilopoulos et al., 2001). Sera from lyn/IFN–/– mice 
also showed a dramatic reduction of ANA staining intensity 
(Fig. S5 D). The lyn/IFN/ animals manifested a re-
markable improvement in the kidney pathology (both inter-
stitial and glomerulonephritis) compared with lyn/ mice, 
with  strongly  reduced  infiltration  of  CD45+  leukocytes 
(mainly Mac-1+ myeloid cells and activated T cells) and no 
formation of IgG immune complex or C3 deposits (Fig. 5 E; 
Fig. S5, E and F; and Table I). Finally, in a similar fashion to 
HFL/ mice, BAFF mRNA expression was also strongly 
reduced in the kidneys of lyn/IFN/ mice (Fig. 5 B, 
deficiency also dramatically reduced both the myeloproliferation 
and T cell activation present in lyn/ mice (Fig. 5, C and D;   
and Fig. S5 A). On the other hand, the phenotype and   
accumulation of activated B lymphocytes and plasma cells   
(in the setting of overall B cell lymphopenia) was mostly un-
changed in lyn/IFN–/– compared with lyn/ mice (Fig. 5 D 
and Fig. S5 B). Although IFN- deficiency reduced the level 
of autoreactive (mainly IgG2a/c) but not total IgG antibodies 
in lyn/ mice, the lyn/IFN–/– animals still overproduced 
total and autoreactive IgM autoantibodies (Fig. S5 C). The 
important role of IFN- in the production of IgG2a/c patho-
genic antibodies in lyn/ mice is in agreement with other 
Figure 4.  Myeloid-specific Lyn deficiency induces elevated BAFF serum levels and autoimmunity. WT, rag/-WT, and lyn/rag/-WT chime-
ras were generated as described in Materials and methods. (A) BAFF serum levels in WT, rag/-WT, and lyn/rag/-WT chimeras, assessed by ELISA. 
Each symbol represents the BAFF serum level of an individual mouse. Horizontal bars represent means. Data are pooled from three independent kinetic 
experiments. (B) Each symbol represents the weight of an individual spleen from 10-mo-old WT, rag/-WT, and lyn/rag/-WT chimeras. Horizontal 
bars represent means. Data are pooled from three independent end-point experiments (n = 6–14). (C) Single-cell suspensions of spleens from 8–10-mo-
old WT, rag/-WT, and lyn/rag/-WT chimeras were counted and stained for FACS analysis. (left) The absolute number of total cells and (right) the 
absolute number of activated lymphocytes, calculated as described for Fig. 3. Data are expressed as means ± SEM (n = 10 mice per group). Statistical dif-
ferences of lyn/rag/-WT versus rag/-WT chimeras or rag/-WT versus WT chimeras are reported. Data are pooled from three independent end-
point experiments. (D) A single-cell suspension of spleens was prepared and the frequencies of IgM-secreting AFCs specific to DNA were assessed by 
ELISPOT in 8–10-mo-old WT, rag/-WT, or lyn/rag/-WT chimeras or lyn/ mice. Statistical differences of lyn/rag/-WT versus rag/-WT chi-
meras are reported. Horizontal bars represent means. Data are representative of five independent experiments. *, P < 0.05; **, P < 0.01; ***, P < 0.001.  
(E) Representative H&E staining of kidneys from 8–10-mo-old WT, rag/-WT, and lyn/rag/-WT chimeras. Bars, 100 µm. Data are representative  
of >20 mice for each genotype analyzed at end-point experiments.1764 BAFF, IFN-, and myeloid cells in autoimmunity | Scapini et al.
lyn/rag/-IFN/ chimeras was lower than in the lyn/ 
rag/ chimeras. These observations suggest that lymphocytes 
(i.e., T or possibly NKT cells), not NK or myeloid cells, are 
the primary source of IFN- necessary to drive myeloprolifer-
ation, BAFF overproduction, and nephritis in lyn/ mice (or 
in animals lacking Lyn in the myeloid compartment alone).
Because genetic deletion of IFN- in lymphocytes blocked 
disease development, we reasoned that treatment with re-
combinant IFN- should accelerate the process. Indeed, both 
lyn/ mice and lyn/rag/-WT chimeras developed se-
vere myeloproliferation, dramatically elevated BAFF produc-
tion, T cell activation, and nephritis after 3 mo of treatment 
with rIFN- (unpublished data). Autoantibody production 
was unaffected and rIFN- treatment had no effect on WT 
right). These results indicate that IFN- contributes to my-
eloproliferation, BAFF overproduction, and T cell activation 
in this model.
To further validate the interrelationship between BAFF 
release by myeloid cells and IFN- production by T cells, we 
generated animals lacking Lyn in the myeloid cell compart-
ment and IFN- in the lymphoid compartment by creating 
lyn/rag/ chimeras mixed with IFN-–deficient bone 
marrow cells. These mixed chimeric animals did not show 
myeloproliferation, had lower levels of BAFF, reduced T cell 
activation, and reduced nephritis (Fig. S6). In contrast to the 
lyn/IFN/ mice, which showed persistent B cell activa-
tion and IgM autoantibody production because of a defi-
ciency of Lyn in B cells, activation of the WT B cells in the 
Figure 5.  IFN- deficiency reduces BAFF serum levels, blocks splenomegaly, and improves autoimmunity in lyn/ mice. (A) BAFF serum 
levels in WT, lyn/, and lyn/IFN/ mice, assessed by ELISA. Each symbol represents the BAFF serum level of an individual mouse. Data are pooled 
from two independent kinetic experiments (n = 5–8). (B) BAFF mRNA expression in sorted splenic macrophages and DCs (F4/80+CD11c+) and total 
spleens (left) or total kidneys (right) from 6–10-mo-old WT, lyn/, or lyn/IFN/ mice. Data are representative of one end-point experiment  
(n = 4). (C) Each symbol represents the weight of an individual spleen from 8–10-mo-old WT, lyn/, or lyn/IFN/ mice. Data are pooled from 
two independent end-point experiments (n = 8–9). Horizontal bars in A–C represent means. (D) Single-cell suspensions of spleens from 8–10-mo-old 
WT, lyn/, or lyn/IFN/ mice were counted and stained for FACS analysis. (left) The absolute number of total cells and (right) the absolute num-
ber of activated lymphocytes, calculated as described for Fig. 3. Data are expressed as means ± SEM (n = 9 mice per group). Statistical differences of 
lyn/IFN/ versus lyn/ mice or lyn/IFN/ versus WT mice are reported. Data are pooled from two independent end-point experiments.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001. (E) Representative H&E staining of kidney sections from 8–10-mo-old WT, lyn/, or lyn/IFN/ mice. Bars, 
100 µm. Data are representative of 10–15 mice for each genotype analyzed at end-point experiments.JEM VOL. 207, August 2, 2010 
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5-mo anti-BAFF mAb treatment induced a clear improvement 
of nephritis in lyn/ mice (both interstitial and glomerulone-
phritis) by reducing IgG (but not IgM) immune complex and 
C3 deposits, as well as the infiltration of myeloid cells and acti-
vated T cells (Fig. 6 E; Fig. S7, D and E; and Table II).
In the 6–7-mo-old lyn/ mice, we performed a 2-mo 
anti-BAFF treatment protocol (short-term treatment). At 
this stage of life, lyn/ mice have large numbers of activated 
B cells, plasma cells, extreme myeloproliferation, very high   
levels of activated T cells (with high IFN- production), and 
established nephritis. After short-term anti-BAFF mAb treat-
ment, the myeloproliferation, T cell activation, and IFN- 
production were strongly reduced in lyn/ mice, whereas 
the number of activated B cells as well as autoantibody and 
total Ig production was minimally affected (Fig. 6, F–I; and 
Fig. S8, A and B). The latter phenomenon was likely caused 
by reduced BAFF receptor expression in fully activated   
B cells and by the shift in dependency of activated mem-
ory or plasma cells on other survival factors besides BAFF 
(Ng et al., 2005; Ramanujam et al., 2006; Ettinger et al., 
2007; Scholz et al., 2008). This short-term treatment of older 
lyn/ mice also partially reversed the extent of nephritis 
by improving mainly the interstitial nephritis and to a lesser   
extent the glomerulonephritis (Fig. 6 J and Fig. S8 C). These 
data indicate that even in older lyn/ mice with well- 
established disease, the anti-BAFF treatment could reduce   
T  cell  activation,  IFN-  production,  and  subsequent   
mice. Thus, in response to elevated IFN-, the hyperreactive 
lyn/ myeloid cells released large amounts of BAFF and in-
duced an accelerated inflammatory/autoimmune process.
Reduction of BAFF activity ameliorates the development  
of autoimmunity in lyn/ mice
Our observations suggest that the dysregulated myeloprolif-
eration  and  BAFF  production  caused  by  Lyn  deficiency 
might lead to increased T cell activation and IFN- release 
that, in turn, could feed back on the myeloid compartment 
to increase hyperreactivity. To directly test the role of BAFF 
in this pathogenic loop, we used a neutralizing anti-BAFF 
mAb  to  reduce  BAFF  activity.  In  line  with  observations   
reported by others (Kalled, 2005; Mackay and Schneider, 
2009), we found that the administration of high doses of neu-
tralizing anti-BAFF mAb (>100 µg/20 g mouse) led to com-
plete and prolonged mature B cell depletion, as well as strong 
reduction in T cell activation, myeloproliferation, and nephri-
tis in lyn/ mice (unpublished data). Because it is well 
known that B cell depletion in autoimmune models leads to 
diminution  of  T  cell  activation  and  disease  amelioration, 
these results were expected (Shlomchik et al., 2001; Yanaba 
et al., 2008; Dörner et al., 2009). However, to better under-
stand the pathological role of BAFF in Lyn-deficient auto-
immunity, we sought to only partially reduce BAFF levels in 
lyn/ mice without producing significant B cell depletion. 
We hypothesized that a reduction in BAFF levels would reduce 
the myeloproliferation, T cell activation, and IFN- over-
production that characterize the lyn/ autoimmune pheno-
type. To partially reduce BAFF activity, we established an 
anti-BAFF dosing regimen using small amounts of anti-BAFF 
mAb administered every other day for several months (see 
Materials and methods). We did this experiment in both 6–8-
wk-old mice, before disease onset, and 6–7-mo-old mice 
with active disease.
In young lyn/ mice (before the onset of myeloprolifer-
ation and significant B or T cell activation) treated every other 
day for 5 mo (long-term treatment), the number and per-
centage of B cells was reduced by 50%, although the distri-
bution of remaining B cell subtypes was similar to untreated 
lyn/ mice (Fig. 6, A and B, left; and Fig. S7 A, left). This 
5-mo anti-BAFF mAb treatment partially reversed the hyper-
reactive phenotype of lyn/ B cells (Fig. 6, A and B, right; 
and Fig. S7 A, right). The serum level of autoreactive IgG 
antibodies (but not IgM) was significantly reduced, whereas 
total Ig levels remained the same (Fig. 6 C and Fig. S7 B). 
Besides these partial effects on B cell activation, the low-dose 
anti-BAFF treatment dramatically reduced both myeloprolifera-
tion and T cell activation in lyn/ mice (Fig. 6, A, B, and D).   
Both the number and percentage of activated and IFN-–
producing T cells (of both the CD4 and CD8 subtypes) was 
strongly reduced in 5-mo anti-BAFF mAb–treated lyn/ 
mice as compared with the isotype control–treated animals 
(Fig. 6, A and B, right). As a result, serum IFN- in the treated 
young lyn/ mice was reduced to almost undetectable levels 
by the anti-BAFF mAb treatment (Fig. S7 C). Finally, the   
Table II.  Reduction of BAFF activity reduces the infiltration 
of leukocytes into the kidneys of lyn/ mice
Treatment lyn/ lyn/ + anti-BAFF 
antibody
CD45+ (×105) 18.5 ± 4 9.8 ± 1.4*
CD45+CD19+ (×105) 0.9 ± 0.2 0.15 ± 0.05**
CD45+Mac-1+ (×105) 12.3 ± 4 5.1 ± 0.6*
CD45+TCR+ (×105) 5.2 ± 0.8 4.5 ± 0.5
CD45+TCR+CD44highCD62L (%) 77 ± 2 52 ± 5***
Histological score
Glomerulonephritis 2.2 ± 0.3 1.1 ± 0.21**
Interstitial nephritis 2 ± 0.2 0.6 ± 0.1***
Immunofluorescence  
staining intensity
IgM deposit score +++ +++
IgG deposit score ++ +/
C3 deposit score +++ +/
Young (2-mo-old) lyn/ mice were treated with neutralizing anti-BAFF mAb or 
irrelevant isotype control mAb for 5 mo (long-term treatment), as described in 
Materials and methods. Mice were sacrificed, and kidneys were isolated, processed, 
and analyzed for infiltration of leukocytes by flow cytometry, as described in 
Materials and methods. The absolute number of total leukocytes (CD45+), B cells 
(CD19+), myeloid cells (Mac-1+), and T cells (TCR+), and the percentage of activated 
effector T cells (TCR+CD44highCD62L) are reported as means ± SEM (n = 7–10).  
*, P < 0.05; **, P < 0.01; ***, P < 0.001. Histological analysis of renal disease as well 
as of Ig immune complex and C3 deposit immunofluorescent staining intensity was 
performed as described in Materials and methods. Data are representative of  
12 mice for each genotype analyzed at end-point experiments.1766 BAFF, IFN-, and myeloid cells in autoimmunity | Scapini et al.
Figure 6.  Reduction of BAFF activity ameliorates autoimmune abnormalities in lyn/ mice. (A–J) Young (2-mo-old) lyn/ mice were treated for 
5 mo (long-term treatment; A–E) or old (6–7-mo-old) lyn/ mice were treated for 2 mo (short-term treatment; F–J) with neutralizing anti-BAFF mAb or 
irrelevant isotype control mAb, as described in Materials and methods. (A, B, F, and G) Single-cell suspensions of spleens from lyn/ mice after 5 mo (A and B)  
or 2 mo (F and G) of treatment with anti-BAFF mAb were counted and stained for FACS analysis. (left) The absolute number (A and F) and percentage  
(B and G) of total cells and (right) the absolute number (A and F) and percentage (B and G) of activated lymphocytes, calculated as described for Fig. 3.  JEM VOL. 207, August 2, 2010 
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which strengthens the argument that deregulation of myeloid 
cell function is a key pathogenic feature in this model. Block-
ing this inflammatory loop by reducing myeloid cell hyper-
reactivity (using HFL/ mice), lowering BAFF (using mAb 
treatment), or removing IFN- (genetically) prevented ne-
phritis in lyn/ animals. Overall, our observations demon-
strate that overproduction of BAFF by innate immune cells 
in a lupus-like disease setting can directly increase T cell acti-
vation and IFN- production by these cells, suggesting that 
this is an additional pathological role of BAFF in this disease 
that may have been underestimated.
Although our observations suggest the establishment of 
an inflammatory loop between myeloid cells and T cells that 
exacerbates autoimmunity in lyn/ mice, it still remains unclear 
what initiates the process. There are several potential mecha-
nisms  for  initiation  of  the  inflammation/autoimmunity  in 
lyn/ mice. First, the intrinsic effects of Lyn deletion on   
B cell tolerance thresholds leads to a degree of B cell activa-
tion, autoantibody production, and tissue deposition of im-
mune complexes to which T cells and lyn/ myeloid cells 
could then hyperrespond. Second, the relative B cell lym-
phopenia and resultant elevated serum BAFF in young lyn/ 
mice may be adequate to promote increased B cell autoim-
mune responses (Schneider, 2005; Sarantopoulos et al., 2007). 
The third possible mechanism may involve myeloid cell hy-
peractivity toward Toll-like receptor (TLR) agonists (present 
in commensal flora or from environmental sources). Silver   
et al. (2007) have recently demonstrated that loss of TLR sig-
naling through MyD88 deficiency prevents development of 
autoimmunity in lyn/ mice, suggesting that chronic stimu-
lation of TLRs by endogenous flora may also contribute to 
the disease. Of course, all three of these mechanisms may 
contribute together toward establishment of the inflamma-
tory loop. However, intrinsic defects in B cells alone are not 
sufficient  to  establish  the  full  autoimmune  phenotype  in 
lyn/ mice, because both the HFL/ and lyn/IFN/ 
animals manifest much of the B cell hyperactivity caused   
by the lack of Lyn, yet neither of these strains develop the   
inflammatory/autoimmune nephritis. These data are in agree-
ment with several reports in the literature revealing that   
autoantibody production alone is not sufficient to produce 
end-organ damage (Chan et al., 1999; Bagavant and Fu, 
2005;  Ramanujam  and  Davidson,  2008).  Furthermore,  in 
other mouse lupus models, BAFF blockade has been shown 
to decrease renal injury and inflammation without inducing a 
strong reduction of immune complex deposition in the   
kidney, suggesting that a direct pathogenic role of BAFF in 
regulating the inflammatory damage in the target organ is   
myeloid cell hyperreactivity without dramatically affecting   
B cell numbers or activation.
BAFF supports T cell activation and IFN- production in vivo
To directly test whether the high BAFF in lyn/ mice can 
directly contribute to the activation of T cells in vivo indepen-
dently from the effect of this cytokine on B cell activation, 
we performed adoptive transfer of WT or BAFF receptor–
deficient (BAFF-R/) T cells into 6–7-mo-old lyn/ mice 
(or WT mice as controls). To perform these experiments, we 
injected a 1:1 ratio mixture of freshly isolated naive splenic 
WT and BAFF-R/ T cells, which could be distinguished 
by differential expression of the congenic marker CD45.1/2. 
15 d after the transfer, we observed no significant changes in 
activation or IFN- production of either WT or BAFF-R/ 
donor T cells when transferred in WT host mice (Fig. 7 A). 
On the other hand, although donor WT T cells transferred in 
lyn/ mice reached levels of activation that were indistinguish-
able from endogenous host lyn/ T cells, the BAFF-R/  
T cells showed much lower levels of CD44, higher expression 
of CD62L, and reduced IFN- expression (Fig. 7, A and B). 
The reduced response in vivo of BAFF-R/ T cells is not 
caused  by  general  functional  impairment  because  BAFF-
R/ T cells develop normally and respond normally to anti-
CD3/anti-CD28 stimulation in vitro (Ng et al., 2004; Mackay 
and Leung, 2006). These data indicate that BAFF-R/ T cells 
show reduced activation and IFN- production when trans-
ferred into lyn/ mice, suggesting that the overproduction of 
BAFF in these animals is a direct contributor to enhanced   
T cell activation.
DISCUSSION
lyn/ mice develop a progressive lupus-like autoimmunity 
that, to date, has been mainly attributed to B cell hyperacti-
vation  and  abnormalities  in  B  cell  tolerance  mechanisms 
(Hibbs et al., 1995; Nishizumi et al., 1995; Chan et al., 1997; 
Xu et al., 2005). Our results demonstrate that the myeloid 
compartment plays a crucial role for development of autoim-
munity in lyn/ mice. We propose that the deregulation of 
myeloid cell responses in lyn/ mice leads to overproduc-
tion of BAFF, which acts on B cells as expected but also acti-
vates T cells, leading to increased IFN- release, which 
further increases myeloid cell hyperactivity. The reciprocal 
production of BAFF and IFN- establishes a self-sustaining 
inflammatory loop that is crucial for progression of autoim-
munity caused by Lyn deficiency (Fig. 8). This inflammatory 
loop also develops in mice having only a Lyn-deficient my-
eloid  compartment  and  a  WT  lymphocyte  compartment, 
Data are expressed as means ± SEM (n = 10–11 mice per group in A and B or 5–6 mice per group in F and G). Date are representative of two independent end-
point experiments. (C and H) Effect of 5 mo (C) or 2 mo (H) of anti-BAFF mAb treatment on the levels of IgM and IgG specific to DNA in lyn/ mice, as-
sessed by ELISA. Data are representative of two independent end-point experiments (n = 10–12). (D and I) Effect of 5 mo (D) or 2 mo (I) of anti-BAFF mAb 
treatment on the development of splenomegaly in lyn/ mice. Data are representative of two independent end-point experiments (n = 10–12). *, P < 0.05; 
**, P < 0.01; ***, P < 0.001. Horizontal bars in C, D, H, and I represent means. (E and J) Representative H&E staining of kidneys from lyn/ mice after 5 mo (E) 
or 2 mo (J) of treatment with anti-BAFF mAb. Bars, 100 µm. Data are representative of 12–16 mice for each treatment analyzed at end-point experiments.
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The interplay between BAFF production by myeloid cells and 
IFN- production by T cells could be a key pathogenic mech-
anism contributing to many aspects of lupus-like disorders.
Although we have focused on overproduction of BAFF 
as playing a central role in the development of autoimmunity 
in lyn/ mice, it is very likely that other cytokines contrib-
ute to the disease process as well. Indeed, we have observed 
elevated levels of IL-6, GM-CSF, and M-CSF in these mice, 
and they too may be involved in the inflammatory/autoim-
mune loop (unpublished data). IL-6 has been found to be in-
volved in the autoimmune process in several mouse model of 
lupus (Liang et al., 2006; Maeda et al., 2009; Cash et al., 
2010) and, more recently, in lyn/ mice (Tsantikos et al., 
2009). Furthermore, a pathological role for myeloid cell– 
specific CSFs, such as M-CSF and GM-CSF, in inflammation 
and autoimmunity has been suggested (Hamilton, 2008). On the 
other hand, both genetic deletion of IFN- and reduction of 
BAFF activity dramatically lowered the serum levels of these 
proinflammatory cytokines (unpublished data). Hence, although 
BAFF and IFN- are probably not the only cytokines involved, 
they are necessary for disease progression in lyn/ mice.
The anti-BAFF mAb treatment experiments provide im-
portant insights into the relationship between BAFF, T cell 
activation, and IFN- production. Although the partial   
(in young lyn/ mice) or minimal (in older lyn/ mice) reduc-
tion in activated B cells and autoantibody production achieved 
by administration of low-dose anti-BAFF mAb was expected, 
the reduction in T cell activation, IFN- production, and 
myeloproliferation in both young and old lyn/ mice was 
unexpected. We have also performed low-dose anti-BAFF 
treatment of lyn/rag/-WT chimeras lacking Lyn in my-
eloid cells only, and have seen similar effects on T cell activa-
tion and myeloproliferation (unpublished data). Our proposal 
that BAFF plays an important role in autoimmune disease in 
part through its effect on T cells is supported by in vitro find-
ings demonstrating that BAFF acts as a co-stimulatory molecule 
to enhance T cell activation and differentiation into IFN-–
secreting cells, mainly through the interaction with BAFF-R 
(Huard et al., 2001; Mackay and Leung, 2006). BAFF effects 
on T cells via BAFF-R have also been shown in vivo in a 
transplantation setting (Ye et al., 2004). Similarly, our observa-
tion that WT T cells become activated and secrete IFN- 
when adoptively transferred into lyn/ mice, whereas BAFF-
R/ T cells show weak responses, supports the notion that 
BAFF is acting directly on T cells. The low level of activation 
still present in BAFF-R/ T cells transferred in lyn/ mice 
is likely caused by other proinflammatory cytokines that sustain/
induce T cell activation (such as TNF and IL-6), which are 
present in lyn/ mice at a late stage of disease.
Collectively, our data indicate that dysregulated BAFF 
production by myeloid cells in response to activated T cell–
derived IFN- establishes an inflammatory loop that is criti-
cal for the progression of autoimmunity in lyn/ mice and, 
potentially, to autoimmune disorders in general (Fig. 8). In 
human lupus patients, an elevated number of IFN-–producing 
effector T cells and BAFF-producing monocytes has been 
independent from the induction of pathogenic IgG autoanti-
bodies (Stohl et al., 2005; Ramanujam et al., 2006; Ramanujam 
and Davidson, 2008; Moisini and Davidson, 2009). Several 
studies have suggested that IFN- plays an important role in 
the progression of nephritis (Theofilopoulos et al., 2001). 
Figure 7.  BAFF-R/ T cells fail to become activated when  
transferred to lyn/ recipients. (A) Resting T cells isolated from single-
cell suspensions of WT (CD45.1/2 het) or BAFF-R/ (CD45.2) mouse 
spleens and lymph nodes were mixed in a 1:1 ratio and injected i.v. into 
6–7-mo-old WT or lyn/ mice (CD45.1). 15 d after transfer, the levels of 
T cell activation and IFN- production in host and donor T cells were ana-
lyzed by taking advantage of the differential expression of the CD45.1/2 
markers by flow cytometry, as described in Materials and methods. The 
percentage of activated/effector (CD44highCD62L) or IFN-–producing 
host and donor (WT or BAFF-R/) T cells detected in the spleens of host 
WT or lyn/ mice 15 d after adoptive transfer are reported. Data are 
expressed as means ± SEM (n = 7 mice per group). Data are pooled from 
two independent experiments. *, P < 0.05; **, P < 0.01. (B) Representative 
FACS plots of CD44 (top), CD62L (middle), or IFN- (bottom) expression by 
host (left) and donor WT (middle) or BAFF-R/ (right) T (TCR+) cells 
detected in the spleens of host lyn/ mice 15 d after adoptive transfer 
are reported. Data are representative of seven mice for each condition.JEM VOL. 207, August 2, 2010 
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lyn/rag/-IFN/ bone marrow chimeras were also generated in selected 
experiments. Chimeras were analyzed starting from 2 mo of age and followed 
for up to 1 yr for evidence of disease (see Materials and methods). The repopu-
lation of the leukocyte compartments and the percentage of CD45.2+ lyn/ 
rag/ or rag/ myeloid cells versus the CD45.1+ WT myeloid/lymphoid 
cells were evaluated as described in Flow cytometry (FACS). All animals were 
kept in a specific pathogen–free facility at the University of California, San 
Francisco (UCSF) and used according to protocols approved by the UCSF 
Committee on Animal Research.
Cell isolation and culture
BMD neutrophils were isolated from B6 and lyn/ mice, as described pre-
viously (Pereira and Lowell, 2003). Immediately after purification, cells were 
suspended at 106 cells/ml in RPMI 1640 medium supplemented with 10% 
(volume/volume)  FBS  (Invitrogen),  100  U/ml  penicillin  G,  100  µg/ml 
streptomycin, and 2 mM l-glutamine (all from UCSF) and incubated at 
37°C in 5% CO2 in the presence or absence of the stimuli indicated in the 
figures for 24 h. Cells were collected and spun at 350 g for 5 min, and the 
resulting supernatants were stored at less than or equal to 20°C. BMD 
macrophages and BMD DCs were prepared from B6 or lyn/ mice, as de-
scribed previously (Pereira and Lowell, 2003; Chu and Lowell, 2005). BMD 
macrophages were used at day 6 of culture, whereas BMD DCs were used 
between days 8 and 10 of culture. Cells were washed, suspended at 106 cells/ml 
in the appropriate complete media without growth factor, plated in 24-well 
tissue culture plates, and incubated at 37°C in 5% CO2 in the presence or 
absence of the stimuli indicated in the figures for 24 or 48 h for RNA or su-
pernatant preparations, respectively. Cells were collected and spun at 350 g 
for 5 min, and the resulting supernatants were stored at less than or equal   
to 20°C. Cell pellets were processed for RNA extractions as described in 
RNA extractions and Taqman… In selected experiments, BMD macro-
phage and BMD DC culture supernatant preparations were run in parallel 
with a proliferation assay by using the CellTiter 96 Aqueous One Solution 
Cell Proliferation Assay (Promega) according to the manufacturer’s instruc-
tions. The following stimuli and recombinant mouse cytokines were used: 
20 ng/ml GM-CSF, 100 ng/ml IL-10, 20 ng/ml TNF, and 100 ng/ml IL-4 
(PeproTech); 100 U/ml IFN- and 500 U/ml mIFN- (Thermo Fisher 
Scientific); 100 ng/ml M-CSF (R&D Systems); and 1 µM fMLP and 50 ng/ml 
PMA (Sigma-Aldrich). For splenic DC and macrophage isolation, single-cell 
reported (Harigai et al., 2008). In view of the well-described 
role of BAFF in autoimmune diseases and of the interest in 
developing therapeutics able to neutralize BAFF (Ding, 2008; 
Ramanujam  and  Davidson,  2008;  Moisini  and  Davidson, 
2009), our study uncovers an important new pathological 
mechanism through which BAFF contributes to late-stage 
autoimmune disease by promoting a pathological cross talk 
between innate and adaptive immunity.
MATERIALS AND METHODS
Mice
lyn/ and HFL/ mice were previously established and backcrossed onto 
the C57BL/6 (B6, carrying the CD45.2 allele) background for 15 generations 
(Meng and Lowell, 1997; Pereira and Lowell, 2003). lyn/ mice on the B6 
background but carrying the CD45.1 allele were generated by crossbreeding 
with congenic WT mice carrying the CD45.1 allele on the B6 background 
(Taconic). Age-matched WT B6 mice (carrying the CD45.2 allele) were 
purchased from Charles River. WT mice heterozygous for the expression of 
both the CD45.1 and CD45.2 allele (WT CD45.1/2 het) mice were gener-
ated by crossbreading B6 (CD45.2) mice with congenic mice carrying the 
CD45.1 allele on the B6 background. IFN/, rag/, and BAFF-R/ 
mice on a B6 background were obtained from the Jackson Laboratory. lyn/ 
IFN/ and lyn/rag/ mice were generated by crossbreeding lyn/ 
mice and IFN/ or rag/ mice, respectively. Bone marrow chimeras 
were generated by injecting lethally irradiated congenic recipients carrying 
the CD45.1 allele on the B6 background (8–12 wk old) with a pool of bone 
marrow cells containing 75% cells from lyn/rag/ mice (or rag/ mice, 
used as controls) carrying the CD45.2 allele, mixed with 25% cells from 
congenic CD45.1 WT mice (6–8 wk old). Lethally irradiated CD45.2 B6 mice 
reconstituted with 100% congenic CD45.1+ WT cells were also generated as 
controls. By this experimental approach, we were able to generate chimeric 
mice with a high level of deletion (75%) of Lyn in the myeloid compart-
ment, whereas the lymphoid compartment was 100% WT. Multiple ratios of 
the mixed lyn/rag/ (or rag/)-WT bone morrow chimeras (50:50% or 
25:75%, respectively) were also generated and tested, but throughout the 
paper only data regarding the 75:25% lyn/rag/ (or rag/)-WT chimeras 
are  reported  because  of  the  more  severe  phenotype.  Mixed  75:25%   
Figure 8.  Proposed model to explain the 
role of BAFF, IFN-, and myeloid cells in 
Lyn-deficient autoimmunity. (A) Under 
normal conditions BAFF is produced in a fixed 
amount from stromal cells, thus regulating 
the size and the maturation status of the  
B cell compartment. (B) During B cell lymphope-
nia, BAFF serum levels rise, and the amount of 
BAFF available per B cell increases. In the Lyn-
deficient model, the elevated serum BAFF 
caused by the B lymphopenia as well as the 
intrinsic hyperactivity of lyn/ B cells con-
tribute to increased B cell responses, leading 
to autoantibody production. This initial  
inflammatory insult is probably sufficient to 
partially activate T cells (which at this point 
can begin to express BAFF-R) and lyn/  
myeloid cells. (C) In more severe inflammatory 
conditions and/or during myeloid cell activa-
tion/proliferation, BAFF production dramati-
cally increases, directly affecting both B cell 
and T cell activation, leading to differentiation 
of the latter cells into IFN-–producing T cells. IFN-, in a positive feedback loop, sustains more myeloid cell activation/proliferation and BAFF production, 
which in turn further amplifies the lymphocyte activation leading to autoimmunity and organ damage.1770 BAFF, IFN-, and myeloid cells in autoimmunity | Scapini et al.
goat anti–mouse BAFF pAb as coating and detection antibodies, respectively) 
according to the manufacturer’s ELISA protocol. IFN- in sera was mea-
sured by ELISA using cytokine-specific paired antibodies (BD) according to 
the manufacturer’s protocol.
ANA immunofluorescence
Serum was diluted 1:40 and used for indirect immunofluorescence on fixed 
Hep-2  ANA  slides  (Bio-Rad  Laboratories),  with  FITC-conjugated  goat 
anti–mouse IgG (Fc fragment specific; Jackson ImmunoResearch Labora-
tories, Inc.) as the detection reagent. Slides were read on an Eclipse TS100 
microscope at a 400× magnification and scored as either a nuclear homoge-
neous and/or nuclear speckled staining pattern by a reader blinded to the 
genotype of the mice.
Serum Ig and autoantibody measurement
Levels of serum IgG (total and specific isotypes) and IgM were quantified 
using ELISA-specific quantification kits (Bethyl Laboratories, Inc.) accord-
ing to the manufacturer’s protocol. For anti-dsDNA Ig ELISA, 96-well flat-
bottom plates (Microtest; BD) were coated with 20 ng/well of linearized 
pUC19 plasmid in 100 mM Tris-HCl. For anti-RNA Ig ELISA, plates 
(Thermo Fisher Scientific) were coated with 500 U/ml of Smith antigen ri-
bonucleoprotein complex antigen (Sm/RNP Ag; Immunovision) in car-
bonate buffer, pH 9.5, overnight at 4°C. After overnight incubation, plates 
were blocked with PBS containing 2% (volume/volume) FBS and 0.05% 
Tween 20 for 1 h. Serial dilutions of sera were added to the plate and incu-
bated for 2 h at room temperature. The assays were developed with horse-
radish  peroxidase–conjugated  goat  anti–mouse  IgM  antibodies  (  chain 
specific) or anti–mouse IgG (Fc fragment or isotype specific; all from Bethyl 
Laboratories, Inc.), respectively. After addition of the tetramethylbenzidine 
substrate (KPL Inc.), the reaction was stopped by adding 1 M phosphoric 
acid (Sigma-Aldrich), and the absorbance at 450 nm (A450) was measured 
with a microplate reader (Spectra Max Plus; MDS Analytical Technologies). 
Results reported are relative to the following serum dilutions: 1:40 for total 
or isotype-specific IgG and 1:160 for IgM anti-DNA/RNA antibodies; and 
1:60,000 for total IgG, 1:25,000 for total IgG1 and Ig2b, 1:12,000 for total 
IgG3 and IgG2a/c, and 1:20,000 for total IgM antibodies.
Western blotting
Cell lysates prepared as previously described (Mócsai et al., 2006) were run 
on SDS-PAGE and immunoblotted using antibodies against p-STAT1 (Abcam) 
and -actin (Cell Signaling Technology), followed by fluorescence-labeled 
secondary antibodies detected with the Odyssey Infrared Imaging System 
(LI-COR Biosciences).
RNA extractions and TaqMan real-time PCR analysis
RNA extractions from purified cells, total spleens, or kidneys were performed 
using an RNeasy kit (QIAGEN) according to the manufacturer’s instruc-
tions. Retrotranscription was performed using the iScript cDNA Synthesis 
Kit (Bio-Rad Laboratories) according to the manufacturer’s instructions. 
Quantitative RT-PCR was performed on a sequence detection instrument 
(ABI 7700; TaqMan; Applied Biosystems). BAFF and HPRT primer pairs 
and probes were described previously (Lesley et al., 2004). Other primers 
pairs and probes used, including their specificity, orientation (F, forward; R, 
reverse), and sequence were as follows: IFN-, (F) 5-TCAAGTGGCATA-
GATGTGGAAGAA-3, (R) 5-TGGCTCTGCAGGATTTTCATG-3,   
and  (probe)  5-TCACCATCCTTTTGCCAGTTCCTCCAG-3;  and 
CXCL10/IP-10, (F) 5-ACTGGAGTGAAGCCACGCA-3, (R) 5-TGA-
TGGAGAGAGGCTCTCTGC-3, and (probe) 5-CCCCGGTGCTGC-
GATGGATGT-3. Values of BAFF, IFN-, or CXCL10/IP-10 mRNA 
were normalized to the values of HPRT mRNA in each sample.
B cell survival
Resting mouse splenic B cells were isolated by a B cell isolation kit (Miltenyi 
Biotec), plated at 4 × 105 cells/well, and cultured in RPMI 1640 complete 
medium (see Cell isolation and culture) containing 2.5 µM -mercaptoethanol 
suspensions were prepared after digestion of spleens with 500 U/ml collage-
nase D (Roche) followed by staining with fluorescent protein allophycocya-
nin (APC)-conjugated anti-F4/80 and anti-CD11c antibodies performed as 
described in the following section. Cells were suspended in PBS containing 
300 nM DAPI (Sigma-Aldrich), 2 mM EDTA, and 2% (volume/volume) 
FBS before sorting using a high-speed sorter (MoFlo; Dako). The isolated 
myeloid cells had a purity of >98%.
Flow cytometry (FACS)
Leukocytes from peripheral blood and single-cell suspensions from spleens 
depleted of red blood cells were counted and resuspended in PBS containing 
2 mM EDTA and 2% (volume/volume) FBS (staining/washing buffer). Kid-
neys were prepared as previously described (Kaneko et al., 2006) and resus-
pended in staining/washing buffer. For flow cytometry, cells were incubated 
for 5–10 min with 0.5 µg/106 cell anti-CD16/CD32 (2.4G2; UCSF) plus 
100 µg purified mouse Ig (Sigma-Aldrich) per 106 cells to block FcRs before 
staining with the following anti–mouse FITC-conjugated, APC-conjugated, 
PE-conjugated, or biotinylated specific antibodies: CD19 (clone 1D3), 
CD21/35 (7G6), CD23 (B3B4), CD69 (H1.2F3), CD138 (281-2), CD11c 
(HL3),  CD11b  (M1/70),  GR-1  (RB6-8C5),  TCR  (H57-597),  CD44 
(IM7), CD62L (MLE-14), CD45.1 (A20), CD45.2 (104), CD45 (30-F11), 
B220 (RA3-6B2), CD86/B7-2 (GL-1), and MHCII (I-Ab, AF6-120.1; all 
from eBioscience or BD); F4/80 (CI:A3-1; AbD Serotec); and anti–mouse 
neutrophil (7/4; Invitrogen). Biotinylated antibodies were followed by 
streptavidin-conjugated APC (eBoscience). After the final wash, cells were 
resuspended in staining/wash buffer containing 1 µg/ml propidium iodide 
(PI; Sigma-Aldrich) for four-color flow cytometry performed on a FACScan 
(BD), and data were analyzed with FlowJo software (Tree Star, Inc.). For in-
tracellular analysis of IFN- production by T cells by flow cytometry, sple-
nocytes were stimulated for 4 h with 50 ng/ml PMA and 1 µg/ml ionomycin 
(Sigma-Aldrich) in the presence of 3 µg/ml brefeldin A (eBioscience). Cells 
were stained extracellularly with PE–conjugated TCR, and fixed and per-
meabilized for intracellular staining with APC-conjugated anti–IFN- mAb 
(XMG1.2; eBioscience). After the final wash, samples were resuspended in 
staining/washing buffer for flow cytometry analysis performed as described.
Kidney histological analysis and immunofluorescence staining
For each mouse, one kidney was processed for flow cytometric analysis (see 
the previous section), whereas the other kidney was cut in half laterally. Half 
of the kidney was fixed in 10% (volume/volume) formalin, embedded in 
paraffin, and stained with hematoxylin and eosin (H&E) by the UCSF Pa-
thology Core. The other half of the kidney was submerged in optimal cutting 
temperature embedding media, snap frozen, sectioned (5 µm), and fixed in 
acetone, and individual sections were stained with FITC-conjugated goat 
anti–mouse IgG (Fc fragment specific) or anti–mouse IgM ( chain specific; 
Jackson ImmunoResearch Laboratories, Inc.), or FITC-conjugated anti–
mouse C3 (Cappel Laboratories). Images of H&E staining were taken on a 
microscope (DMLB; Leica) at 400 and 100× magnifications, whereas images 
of immunofluorescent staining were taken on a microscope (Eclipse TS100; 
Nikon) at a 200× magnification. The presence and severity of nephritis were 
determined on H&E-stained sections by an expert pathologist blinded to the 
mouse genotype. The severity of disease in the glomerular and interstitial 
compartment was arbitrarily graded as 0 (absent), 1 (mild), 2 (moderate), or 
3 (severe). Morphological analysis involved assessment of the following: for 
glomerulonephritis, glomerular hypercellularity, glomerular size, and pres-
ence of glomerual sclerosis; and for interstitial nephritis, infiltration of mono-
nuclear cells and loss of normal architecture. No clear sign of vasculitis was 
observed in any of the experimental conditions tested. Immunofluorescence 
intensity of Ig immune complex and C3 deposits were subjectively graded in 
a blinded analysis as  (absent), + (minimal), ++ (mild), or +++ (severe).
Cytokine assays
BAFF concentrations in sera, cell-free supernatants, and cell-associated pellets 
were measured by ELISA using cytokine-specific antibodies from R&D   
(1 µg/ml rat anti–mouse BAFF mAb [clone 121808] and 15 ng/ml biotinylated JEM VOL. 207, August 2, 2010 
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that the genetic deletion of Hck/Fgr reduces myeloproliferation in lyn/ 
mice, whereas production of autoreactive autoantibodies and B cell hyper-
activation are not affected. Fig. S4 shows that lyn/rag/-WT chimeras 
develop myeloproliferation and increased amounts of autoreactive IgM in 
the sera. Fig. S5 shows that genetic deletion of IFN- reduces myelopro-
liferation as well as IgG immune complex and C3 deposits in the kidneys 
in lyn/ mice. Fig. S6 shows that IFN- deficiency in the lymphoid com-
partment reduces BAFF serum levels, blocks splenomegaly, and improves 
autoimmunity in lyn/rag/ -WT chimeras. Fig. S7 depicts the effect of 
long-term anti-BAFF mAb treatment on lyn/ B cell subtypes and hyperac-
tivation, IFN- serum levels, and Ig immune complex and C3 deposits in the 
kidneys. Fig. S8 depicts the effect of short-term anti-BAFF mAb treatment 
on lyn/ B cell subtypes and hyperactivation. Online supplemental material 
is available at http://www.jem.org/cgi/content/full/jem.20100086/DC1.
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ELISPOT
To determine the frequency of antibody-forming cells (AFCs) specific for 
dsDNA,  96-well  filter  plates  (MultiScreenHTS;  Millipore)  were  coated 
overnight at 4°C with 10 µg/ml of linearized pUC19 plasmid in 100 mM 
Tris-HCl. Plates were blocked with PBS containing 1% (weight/volume) 
BSA (Sigma-Aldrich) for 1 h at 37°C. Freshly isolated splenocytes were re-
suspended in RPMI 1640 complete medium containing 2% (volume/volume) 
FBS and 2.5 µM -mercaptoethanol, plated in duplicate at multiple dilutions 
(starting with 106), and incubated overnight at 37°C in 5% CO2. 1 µg/ml of 
biotin-conjugated rat anti–mouse IgM (clone II/41; BD), alkaline phosphatase–
conjugated streptavidin (1:500 dilution; KPL Inc.), and BCIP/NBT phos-
phatase substrate (KPL Inc.) were used for detection. DNA-specific spots 
were read with an ELISPOT reader (Transtec 1300; AID Diagnostika) and 
reported as the mean number of AFCs for 105 B cells.
Anti–mouse BAFF and recombinant mouse IFN-  
treatment regimens
Anti-BAFF mAb treatment. Long-term anti-BAFF mAb treatment was 
performed starting from 6–8 wk of age in lyn/ mice by giving intraperitoneal 
injections of 2–3 µg/20 g of body weight of neutralizing hamster anti-BAFF 
mAb (clone 10F4B; provided by Human Genome Sciences; Scholz et al., 2008) 
or isotype control mAb (BD) every other day for 5 mo. Short-term anti-
BAFF mAb treatment was performed under a similar dose/frequency regi-
men but for 2 mo starting when the mice were 6–7 mo old. To establish the 
dosing regimen that led to reduced autoreactive B cell clones without induc-
ing a complete depletion of mature B cells, mice were bled every 2–3 wk and 
serum levels of BAFF, total Ig, and autoantibodies were measured as described in 
Serum Ig and autoantibody measurement. The percentage of peripheral B cells 
was analyzed by flow cytometry as described in Flow cytometry (FACS).
rIFN- treatment. Starting from 8 wk of age, mice were given intraperi-
toneal injections of 5 × 104 U rIFN- or saline as a control three times 
weekly for a period of 3 mo. Mice were bled every 2–3 wk and followed up 
as described for the anti-BAFF mAb treatment.
Adoptive T cell transfers
Resting T cells were isolated from single-cell suspensions of WT (CD45.1/2 
het) or BAFF-R/ (CD45.2) mouse spleens and lymph nodes using a T cell 
isolation kit (Miltenyi Biotec) according to manufacturer’s instructions. Purified 
WT or BAFF-R/ T cells were mixed in a 1:1 ratio, and a total of 1.2 × 107 
cells in 200 µl of saline solution were injected i.v. into 6–7-mo-old WT or 
lyn/ mice (CD45.1). 15 d after transfer, the spleens of host mice were   
harvested and the levels of T cell activation and IFN- production in host 
and donor T cells were analyzed by taking advantage of the differential   
expression of the CD45.1/2 markers by flow cytometry, as described in Flow 
cytometry (FACS).
Statistical analysis
Significance was determined with the unpaired two-tailed Student’s t test.
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